Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Solarboom 2024: Fünf Gründe, die für diese Aktie sprechen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
537 Leser
Artikel bewerten:
(2)

Lithuania is First of Baltic States to Begin Intracranial Radiosurgery With Elekta's Leksell Gamma Knife

100th Leksell Gamma Knife Icon begins operations at Kaunos Klinikos

KAUNAS, Lithuania, Sept. 6, 2019 /PRNewswire/ -- Doctors at Kaunos Klinikos (Kaunas, Lithuania) have ushered in the era of advanced stereotactic intracranial radiosurgery in Lithuania and the Baltic States (Estonia, Latvia, Lithuania) as they have begun treating patients using their new Leksell Gamma Knife Icon. The sophisticated imaging and motion management technology in Icon enables doctors to precisely treat brain tumors and other cerebral disorders in a single or multiple sessions using either frame- or mask-based options. To date, Kaunos Klinikos has used its Icon system to treat 62 patients, an average of 6 per week.

"The first patient was a 56-year-old male patient with a skull-based recurrent meningioma that we were able to safely treat in five sessions using a thermoplastic mask to immobilize his head," says Professor Arimantas Tamašauskas, MD, PhD and Head of Department of Neurosurgery. "On the same day we also treated a 78-year-old woman suffering from essential tremor. In this case, we used a frame-based option with Icon and delivered a very high (130 Gy) single dose."

The third patient's case highlighted the well-known benefits of Gamma Knife radiosurgery in treating multiple cerebral metastases (mets). "We were able to help this patient avoid whole brain radiation therapy (WBRT), using Icon to treat 25 mets," Tamašauskas says. "The remaining two patients on our first day with Icon were treated for cavernous sinus meningioma."

In just two months since Kaunos Klinikos began using Icon, it has compiled an impressive record: 62 patients treated in 82 treatment sessions and encompassing a broad spectrum of indications treated with Gamma Knife, including single and multiple metastases, meningiomas, essential tremor, ophthalmologic melanoma, arteriovenous malformation, vestibular schwannoma, and trigeminal neuralgia.

The introduction of Gamma Knife technology in the Baltic States is a major benefit, not only for the region, but for more distant countries, he adds. To date, over 1.2 million patients have been treated worldwide with Leksell Gamma Knife. In its first year of operation, Dr. Tamašauskas predicts Kaunos Klinikos will treat over 300 patients with Icon.

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Public Affairs
Tel: +46-70-410-7180, e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1-770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/elekta/r/lithuania-is-first-of-baltic-states-to-begin-intracranial-radiosurgery-with-elekta-s-leksell-gamma-k,c2896854

The following files are available for download:

https://mb.cision.com/Main/35/2896854/1101081.pdf

Release

https://news.cision.com/elekta/i/elekta-icon-pnt-dctr-nb-40-3x20-47cm-300dpi-f,c2677593

Elekta Icon pnt dctr nb 40-3x20-47cm 300dpi f

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2019 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.